Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

DNTH

Dianthus Therapeutics Inc

Apr 20 • 03:01PM ET

92.64

-0.62 -0.67 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI IWM XBI VXF IWN SCHA VTWO VHT IWC DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.11	Insider Own	16.67%	Shs Outstand	52.94M	Perf Week	2.93%
Market Cap	5.04B	Forward P/E	-	EPS next Y	-4.81	Insider Trans	-6.04%	Shs Float	44.12M	Perf Month	15.79%
Enterprise Value	4.64B	PEG	-	EPS next Q	-1.06	Inst Own	85.93%	Short Float	20.56%	Perf Quarter	110.06%
Income	-162.34M	P/S	2472.48	EPS this Y	-2.37%	Inst Trans	6.82%	Short Ratio	8.57	Perf Half Y	157.32%
Sales	2.04M	P/B	8.12	EPS next Y	-11.77%	ROA	-35.85%	Short Interest	9.07M	Perf YTD	124.79%
Book/sh	11.42	P/C	12.48	EPS next 5Y	-9.19%	ROE	-38.38%	52W High	96.50 -4.01%	Perf Year	375.05%
Cash/sh	7.43	P/FCF	-	EPS past 3/5Y	49.46% 31.21%	ROIC	-32.83%	52W Low	16.64 456.87%	Perf 3Y	659.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-31.80% -	Gross Margin	78.98%	Volatility	4.32% 5.43%	Perf 5Y	-45.43%
Dividend TTM	-	EV/Sales	2274.98	EPS Y/Y TTM	-58.36%	Oper. Margin	-8739.34%	ATR (14)	4.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.32	Sales Y/Y TTM	-67.35%	Profit Margin	-7973.33%	RSI (14)	68.07	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	13.32	EPS Q/Q	-76.48%	SMA20	6.78%	Beta	1.25	Target Price	126.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-78.58%	SMA50	28.70%	Rel Volume	0.37	Prev Close	93.26
Employees	92	LT Debt/Eq	0.00	Earnings	Mar 09 BMO	SMA200	110.93%	Avg Volume	1.06M	Price	92.64
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-42.18% -48.57%	Trades		Volume	337,028	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Wolfe Research	Outperform	$98
Mar-10-26	Upgrade	Raymond James	Outperform → Strong Buy	$123
Oct-14-25	Initiated	Truist	Buy	$56
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20

Show Previous Ratings

Apr-06-26 04:01PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 04:01PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.43%
Mar-11-26 06:05AM	Dianthus 7.3M share Secondary priced at $81.00 (TipRanks)
Mar-10-26 10:54PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering (GlobeNewswire) +9.71%
08:02AM	Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) (Insider Monkey)
04:25PM	Loading…
Mar-09-26 04:25PM	Dianthus Therapeutics Has Appreciated 12-Fold Over Two Years. What's Going On? (Investor's Business Daily) +21.52%
04:01PM	Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering (GlobeNewswire)
09:22AM	Dianthus Therapeutics Stock Rallies-Rare Disease Study Success Fuels Optimism (Benzinga)
08:25AM	Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:09AM	Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results (GlobeNewswire)
07:00AM	Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire)
Mar-08-26 05:00PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire)
Mar-05-26 08:44AM	Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? (Zacks)
Mar-04-26 09:25AM	Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +11.99%
Mar-03-26 04:01PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Feb-24-26 07:00AM	Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-13-26 10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
Feb-05-26 07:00AM	Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jan-05-26 07:00AM	Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.03%
Dec-23-25 06:00AM	Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
Dec-05-25 06:35PM	Ashland, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-24-25 07:00AM	Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.38%
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.00%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Dianthus Therapeutics to Participate in Four Investor Conferences During November (GlobeNewswire)
Oct-30-25 10:00AM	Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-25 03:30PM	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting (GlobeNewswire)
Oct-16-25 07:00AM	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases (GlobeNewswire)
08:00AM	Loading…
Oct-02-25 08:00AM	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting (GlobeNewswire) -5.14%
Sep-30-25 11:50AM	Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target (Insider Monkey)
Sep-19-25 03:26PM	Dianthus, Opendoor, and More Stocks See Action From Activist Investors (Barrons.com) -5.45%
Sep-11-25 04:07PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-09-25 10:35PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering (GlobeNewswire) +11.86% +6.55%
10:57AM	Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential (Insider Monkey)
07:15AM	Dianthus to take gMG mAb to Phase III after mid-stage win (Clinical Trials Arena)
Sep-08-25 04:00PM	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering (GlobeNewswire) +20.00%
02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
01:21PM	Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again (Investor's Business Daily)
07:00AM	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile (GlobeNewswire)
Sep-07-25 06:25PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-13-25 04:04PM	The Oncology Institute Announces Changes to Board of Directors (GlobeNewswire)
Aug-07-25 05:20PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.08%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
Aug-06-25 06:45PM	Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savitz Ryan	EVP, CFO & CBO	Apr 09 '26	Option Exercise	17.88	8,224	147,045	8,224	Apr 10 04:52 PM
Savitz Ryan	EVP, CFO & CBO	Apr 09 '26	Sale	89.84	8,224	738,844	0	Apr 10 04:52 PM
RYAN SAVITZ	Officer	Apr 09 '26	Proposed Sale	87.48	8,224	719,436		Apr 09 04:22 PM
Savitz Ryan	EVP, CFO & CBO	Mar 31 '26	Option Exercise	11.74	114,367	1,342,857	114,367	Apr 01 05:26 PM
Savitz Ryan	EVP, CFO & CBO	Mar 31 '26	Sale	83.00	114,367	9,492,596	0	Apr 01 05:26 PM
Soteropoulos Paula	Director	Mar 31 '26	Option Exercise	8.44	599	5,056	599	Apr 01 05:26 PM
Soteropoulos Paula	Director	Mar 31 '26	Sale	80.11	599	47,986	0	Apr 01 05:26 PM
RYAN SAVITZ	Officer	Mar 31 '26	Proposed Sale	79.45	114,367	9,086,458		Mar 31 04:25 PM
PAULA C SOTEROPOULOS	Director	Mar 31 '26	Proposed Sale	79.45	1,198	95,181		Mar 31 04:21 PM
Soteropoulos Paula	Director	Mar 24 '26	Option Exercise	8.44	27,594	232,893	27,594	Mar 26 06:00 PM
Soteropoulos Paula	Director	Mar 24 '26	Sale	78.05	27,594	2,153,712	0	Mar 26 06:00 PM
PAULA C SOTEROPOULOS	Director	Mar 24 '26	Proposed Sale	79.32	27,594	2,188,756		Mar 24 04:29 PM
Garcia Marino	CEO AND PRESIDENT	Mar 16 '26	Option Exercise	7.66	65,292	499,975	65,292	Mar 17 05:22 PM
Garcia Marino	CEO AND PRESIDENT	Mar 12 '26	Option Exercise	6.70	122,918	823,551	122,918	Mar 13 08:30 PM
Garcia Marino	CEO AND PRESIDENT	Mar 12 '26	Sale	81.49	122,918	10,016,381	0	Mar 13 08:30 PM
CARR EDWARD	CHIEF ACCOUNTING OFFICER	Mar 12 '26	Option Exercise	20.45	43,682	893,259	43,682	Mar 13 08:30 PM
CARR EDWARD	CHIEF ACCOUNTING OFFICER	Mar 12 '26	Sale	81.49	43,682	3,559,495	0	Mar 13 08:30 PM
Randhawa Simrat	EVP, Head of R&D	Mar 12 '26	Option Exercise	18.15	33,830	614,166	33,830	Mar 13 08:30 PM
Randhawa Simrat	EVP, Head of R&D	Mar 12 '26	Sale	81.48	33,830	2,756,468	0	Mar 13 08:30 PM
MARINO GARCIA	Director	Mar 12 '26	Proposed Sale	85.84	122,918	10,551,281		Mar 12 04:59 PM
SIMRAT RANDHAWA	Officer	Mar 12 '26	Proposed Sale	85.84	33,830	2,903,967		Mar 12 04:30 PM
EDWARD CARR	Officer	Mar 12 '26	Proposed Sale	85.84	43,682	3,749,663		Mar 12 04:23 PM
Savitz Ryan	CFO & CBO	Dec 04 '25	Option Exercise	8.44	20,000	168,800	20,000	Dec 05 08:00 PM
Savitz Ryan	CFO & CBO	Dec 04 '25	Sale	45.18	20,000	903,600	0	Dec 05 08:00 PM
RYAN SAVITZ	Officer	Dec 04 '25	Proposed Sale	43.97	20,000	879,400		Dec 04 04:42 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Option Exercise	20.42	109,031	2,226,263	113,031	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Option Exercise	8.82	87,507	771,873	91,507	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Sale	38.14	109,031	4,158,442	4,000	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Sale	36.81	87,507	3,221,445	4,000	Nov 14 09:00 PM
SIMRAT RANDHAWA	Officer	Nov 13 '25	Proposed Sale	38.72	196,538	7,609,951		Nov 13 04:23 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Option Exercise	8.44	20,000	168,800	20,000	Sep 11 05:20 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Sale	35.00	20,000	700,000	0	Sep 11 05:20 PM
RYAN SAVITZ	Officer	Sep 09 '25	Proposed Sale	31.80	20,000	636,000		Sep 09 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DNTH

Dianthus Therapeutics Inc

Upgrade your Finviz experience